Ronald H.W. Cooper

Ronald H.W. Cooper

Chief Executive Officer and PresidentatenGene Therapeutics· In proxies 2024–2025

Pay in FY2025-32% from the year before · enGene Therapeutics stock -18.5% the same year

Ronald H.W. Cooper was paid $5.8M in FY2025 (Oct), down 32%. enGene Therapeutics stock fell 18.5% that year.

Pay$100 in the stock at the end of FY24 → $81
Pay is from the Summary Compensation Table of each enGene Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. enGene TherapeuticsPublic company · 2 yr
    • Chief Executive Officer and President2024 – Present · 2 yrStock in role -92%
  2. C4 Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Generation Bio Co.Public company · 5 yr
    • Director2021 – 2026 · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?